Ponatinib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ponatinib |
| DrugBank ID | DB08901 |
| Brand Names (EU) | Iclusig |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.30% |
Approved Indication (EMA)
Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment wit
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | chronic myelogenous leukemia, BCR-ABL1 positive | 99.30% | DL |
| 2 | fibromatosis, gingival | 99.04% | DL |
| 3 | liposarcoma | 99.00% | DL |
| 4 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | 98.98% | DL |
| 5 | ovarian myxoid liposarcoma | 98.93% | DL |
| 6 | hamartoma of lung | 98.93% | DL |
| 7 | fibroma of lung | 98.87% | DL |
| 8 | junctional epidermolysis bullosa | 98.86% | DL |
| 9 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | 98.83% | DL |
| 10 | lung benign neoplasm | 98.83% | DL |
| 11 | lung hilum carcinoma | 98.81% | DL |
| 12 | Ewing sarcoma | 98.79% | DL |
| 13 | familial thrombocytosis | 98.77% | DL |
| 14 | pulmonary sulcus neoplasm | 98.75% | DL |
| 15 | lung germ cell tumor | 98.75% | DL |
| 16 | reactive thrombocytosis | 98.72% | DL |
| 17 | ovarioleukodystrophy | 98.53% | DL |
| 18 | lung cancer | 98.36% | DL |
| 19 | junctional epidermolysis bullosa, non-Herlitz type | 98.35% | DL |
| 20 | dehydratase deficiency | 98.06% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.